Review Article
‘Lipoproteins, glycoxidation and diabetic angiopathy’
Article first published online: 23 JUN 2004
DOI: 10.1002/dmrr.491
Copyright © 2004 John Wiley & Sons, Ltd.
Issue
1520-7560/asset/cover.gif?v=1&s=518ef24df4af0f53197d5b36e1afedd4421360a2)
Diabetes/Metabolism Research and Reviews
Volume 20, Issue 5, pages 349–368, September/October 2004
Additional Information
How to Cite
Jenkins, A. J., Best, J. D., Klein, R. L. and Lyons, T. J. (2004), ‘Lipoproteins, glycoxidation and diabetic angiopathy’. Diabetes/Metabolism Research and Reviews, 20: 349–368. doi: 10.1002/dmrr.491
Publication History
- Issue published online: 26 AUG 2004
- Article first published online: 23 JUN 2004
- Manuscript Accepted: 18 APR 2004
- Manuscript Revised: 13 APR 2004
- Manuscript Received: 29 MAY 2003
- Abstract
- Article
- References
- Cited By
Keywords:
- lipoproteins;
- advanced glycation end-products;
- oxidation;
- diabetes;
- vascular disease
Abstract
The chronic vascular complications of diabetes (nephropathy, retinopathy and accelerated atherosclerosis) are a major cause of morbidity and premature mortality. In spite of the more widespread availability of intensive diabetes management, approximately one in three people with diabetes develop aggressive complications and over 70% die of atherosclerosis-related diseases. Genetic and acquired factors are likely to be contributory. Potential mediators of vascular damage may include the interrelated processes of lipoprotein abnormalities, glycation, oxidation and endothelial dysfunction. Lipoprotein abnormalities encompass alterations in lipid concentrations, lipoprotein composition and subclass distribution and lipoprotein-related enzymes. Nonenzymatic glycation and oxidative damage to lipoproteins, other proteins and to vascular structures may also be deleterious. As atherosclerosis is a chronic condition commencing in youth, and because clinical events may be silent in diabetes, surrogate measures of vascular disease are important for early identification of diabetic patients with or at high risk of vascular damage, and for monitoring efficacy of interventions. The increasing array of biochemical assays for markers and mediators of vascular damage, noninvasive measures of vascular health, and therapeutic options should enable a reduction in the excessive personal and economic burden of vascular disease in type 1 and type 2 diabetes. Copyright © 2004 John Wiley & Sons, Ltd.

1520-7560/asset/bannerforeground.jpg?v=1&s=97ddd213ca98f827538987e02b801875335d1a52)